Lyell Immunopharma (LYEL) EBITDA Margin Growth (1y) (2021 - 2026)
Lyell Immunopharma (LYEL) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,552.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1,049.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -139.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -139.35 Mn |
| Dec 31, 2025 | -29.88 Mn |
| Sep 30, 2025 | -9.98 Mn |
| Jun 30, 2025 | -19.29 Mn |
| Mar 31, 2025 | 103.30 Mn |
| Dec 31, 2024 | -137.09 Mn |
| Sep 30, 2024 | 8.76 Mn |
| Jun 30, 2024 | -15.23 Mn |
| Mar 31, 2024 | -175.63 Mn |
| Dec 31, 2023 | -45.77 Mn |
| Sep 30, 2023 | 197.84 Mn |
| Jun 30, 2023 | -24.40 Mn |
| Mar 31, 2023 | -8.38 Mn |
| Dec 31, 2022 | 165,400.00 |
| Sep 30, 2022 | -221.28 Mn |
| Jun 30, 2022 | 228,186.00 |
| Mar 31, 2022 | -1.01 Mn |
| Dec 31, 2021 | 2,497.00 |
| Sep 30, 2021 | 165,884.00 |
| Jun 30, 2021 | 90,337.00 |